来那度胺为基础的反应适应疗法用于无高危特征老年多发性骨髓瘤患者
这项II期研究评估了不适合高剂量治疗及干细胞移植、无高危特征的初诊老年多发性骨髓瘤患者接受反应适应疗法(单用来那度胺,疾病进展时加低剂量地塞米松)的疗效与安全性。27例入组患者中20例(74%)达部分缓解或更好;中位随访69个月,中位无进展生存期36个月(95%CI 29.8至未达到),中位总生存期65个月(95%CI 35.3至未达到);3/4级不良事件主要为血液学毒性。作者认为该疗法可行、缓解持久,与同期来那度胺联合地塞米松方案相比结果有利,并认为这些结果应在前瞻性研究中验证。
要点
- 27例无高危特征、不适合移植的初诊老年骨髓瘤患者接受单用来那度胺、进展时加低剂量地塞米松的反应适应疗法。
- 20例(74%)达部分缓解或更好;中位无进展生存期36个月(95%CI 29.8至未达到),中位总生存期65个月(95%CI 35.3至未达到)。
- 3/4级不良事件主要为血液学毒性;作者认为该疗法可行,结果应在前瞻性研究中验证。
核心结论
- 作者认为,该反应适应疗法用于无高危特征、不适合高剂量治疗及干细胞移植的初诊老年多发性骨髓瘤患者是可行的,可产生持久缓解,与同期来那度胺联合地塞米松方案相比结果有利;这些结果应在前瞻性研究中验证。
研究设计与样本
- II期研究,评估无高危特征、不适合高剂量治疗及干细胞移植的初诊老年多发性骨髓瘤患者的反应适应疗法:起始单用来那度胺,疾病进展时加用低剂量地塞米松。
- 主要终点为无进展生存期(PFS),采用国际骨髓瘤工作组统一疗效标准评估缓解与进展。
- 共入组27例患者。
主要发现
- 27例患者中20例(74%)对反应适应疗法达部分缓解或更好。
- 中位随访69个月时,中位无进展生存期为36个月(95%CI 29.8至未达到),中位总生存期为65个月(95%CI 35.3至未达到)。
- 3/4级不良事件主要为血液学毒性。
临床怎么用
- 作者认为该反应适应疗法在该患者人群中可行,可产生与同期来那度胺联合地塞米松相比结果有利的持久缓解;作者认为这些结果应在前瞻性研究中验证。
局限性
- 作者指出这些结果应在前瞻性研究中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Combined lenalidomide and dexamethasone is a standard-of-care therapy for the treatment of older adults with multiple myeloma. Lenalidomide monotherapy has not been evaluated in newly diagnosed myeloma patients. We conducted a phase II study, evaluating a response-adapted therapy for older adults newly diagnosed with multiple myeloma without high-risk features who were ineligible for high-dose therapy and stem cell transplant. Patients were started on single-agent lenalidomide, and low-dose dexamethasone was added in the event of progressive disease, in a response-adapted approach. The primary endpoint was progression-free survival (PFS), and the International Myeloma Working Group's uniform response criteria were used to assess response and progression. Twenty-seven patients were enrolled, and 20 (74%) experienced a partial response or better to this response-adapted therapy. After a median follow-up of 69 months, the median PFS was 36 months [95% confidence interval (CI), 29·8 to not reached], and the median overall survival was 65 months (95% CI, 35·3 to not reached). Grade 3/4 adverse events were mainly haematological in nature. This response-adapted therapy in this patient population is feasible and results in durable responses that compare favourably with concurrent lenalidomide and dexamethasone. These results should be validated in prospective studies.
引用
- Baz R, Naqvi SMH, Lee JH, et al. Lenalidomide-based response-adapted therapy for older adults without high risk myeloma. Br J Haematol. 2018. PMID: 30548250. doi:10.1111/bjh.15700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。